Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: A multiparametric and immunohistochemical analysis

Journal of Pathology

Volumn 184, Issue 2, 1998, Pages 130-135

  Jacquemier, Jocelyne D ^a   Penault Llorca, Frederique M ^a   Bertucci, Francois ^a   Sun, Zhen Z ^a   Houvenaeghel, Gilles F ^a   Geneix, Jeanine A ^a   Puig, Brigitte D ^a   Bardou, Valerie Jeanne H ^a   Hassoun, Jacques A ^a   Birnbaum, Daniel ^a   Viens, Patrice J ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Adjuvant chemotherapy; Angiogenesis; Breast cancer; CD31; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MITOXANTRONE;

ANGIOGENESIS; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECEPTOR DENSITY; TUMOR VASCULARIZATION;

ANTIGENS, CD31; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 19244371556     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199802)184:2<130::AID-PATH19>3.0.CO;2-W     Document Type: Article

References (44)

1. Weidner N, Semple JP, Welch WR, Folkman J. Tumour angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
2. Weidner N, Folkman J, Pozza F, et al. Tumour angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 24: 1875-1887.
3. Bosari S, Lee AKC, DeLellis RA, et al. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755-761.
4. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/ endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1220-1124.
5. Van Hoef MEHM, Knox WF, Dhesi SS, Howell AL, Schor AM. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993; 8: 1141-1145.
6. Toi M, Kashitani J, Tominaga T. Tumour angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 1993; 55: 371-374.
7. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 1993; 54: 363-370.
8. Axelson K, Ljung BME, Moore DH II, et al. Tumour angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995; 87: 997-1008.
9. Charpin C, Devictor B, Bergeret D, et al. CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors. Am J Clin Pathol 1995; 103: 443-448.
10. Costello P, McCann A, Carney DN, Dervan PA. Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 1995; 26: 1181-1184.
11. De Jong JS, Van Diest PJ, Baak JPA. Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab Invest 1995; 6: 922-926.
12. Ellis LM, Fidler IJ. Angiogenesis and breast cancer metastasis. Lancet 1995; 346: 388-389.
13. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkey count, and computer image analysis. J Pathol 1995; 177: 275-283.
14. Gasparini G, Harris AL. Clinical importance of the determination of tumour angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13: 765-782.
15. Goulding H, Nik Abdul Rachid NF, Robertson JF, et al. Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Hum Pathol 1995; 26: 1196-1200.
16. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996; 88: 1764-1769.
17. Obermair A, Kurz C, Czerwenka K, et al. Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. Int J Cancer 1995; 62: 126-131.
18. Fox SB. Tumour angiogenesis and prognosis. Histopathology 1997; 30: 294-301.
19. Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994; 74: 2956-2963.
20. Jacquemier J, Penault-Llorca F, Viens P, et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res 1994; 14: 2773-2778.
21. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-1266.
22. Têtu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 2359-2365.
23. Aas T, Børrensen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 7: 811-814.
24. Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 1996; 2: 1509-1513.
25. Silvestrini R, Benini E, Veneroni S. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996; 14: 1604-1610.
26. Protopapa E, Delides GS, Revesz L. Vascular density and the response of breast carcinomas to mastectomy and adjuvant chemotherapy. Eur J Cancer 1993; 10: 1391-1393.
27. Gasparini G, Bonoldi E, Viale G, et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 1996; 69: 205-211.
28. Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D, Rouesse J. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1010 patients uniformly treated at the Institute Gustave Roussy. J Clin Oncol 1987; 5: 1378-1386.
29. Elston CW, Ellis IO. Pathological prognostic factor in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology 1991; 19: 403-410.
30. Jacquemier J, Charpin C, Martin PM. Etude immunohistochimique par anticorps monoclonal (H222SPγ°) des récepteurs oestrogéniques: corrélations avec l'analyse biochimique par radioligand pour 115 carcinomas mammaires. Bull Cancer 1986; 73: 107-119.
31. Jacquemier J, Molès JP, Penault-Llorca F, et al. P53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 1994; 69: 846-852.
32. Penault-Llorca F, Adélaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of EZRBB2 in human breast cancer: impact of fixation. J Pathol 1994; 173: 65-75.
33. Vermeulen PB, Libura M, Libura J, et al. Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Breast Cancer Res Treatment 1997; 42: 165-172.
34. Barbareschi M, Weidner N, Gasparini G, et al. Microvessel density quantification in breast carcinomas. Appl Immunohistochem 1995; 3: 75-84.
35. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 1995; 346: 1334-1335.
36. Paulsen T. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. Int J Cancer 1997; 74: 138-140.
37. Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995; 87: 1237-1245.
38. Wang JM, Kumar S, Pye D, Haboubi N, Al-Nakib L. Breast carcinoma: comparative study of tumour vasculature using two endothelial cell markers. J Natl Cancer Inst 1994; 86: 386-387.
39. Remvikos Y, Beuzoboc P, Zadjela A, Voillemot N, Magdalénat H, Pouillard P. Correlation of pre-treatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 1989; 81: 1383-1387.
40. Spyratos F, Britfod M, Tubiana-Hulin M, et al. Sequential cytopunctures during pre-operative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy tumour regression and short-term follow-up. Cancer 1992; 69: 470-475.
41. Marmé D. Tumour angiogenesis: a new target for cancer therapy. Exp Opin Invest Drugs 1995; 4: 1179-1181.
42. Baillie CT, Winslet MC, Bradley NJ. Tumour vasculature - a potential therapeutic target. Br J Cancer 1995; 72: 257-267.
43. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997; 349 (Suppl II): 13-15.
44. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997; 24: 203-218.